Discover

PHAT
Phathom Pharmaceuticals, Inc.
8.51
1 x 8.40
5 x 8.93
bid
ask
-
0.06
0.70%
2 @ 04:00 PM
8.50 -0.01 (0.12%)
Ytd-48.70%
1y-17.22%
8.46
day range
8.82
8.21
52 week range
18.31
Open8.61Prev Close8.57Low8.46High8.82Mkt Cap688.47M
Vol0.00Avg Vol1.31MEPS-1.47P/E-5.79Forward P/E7.60
Beta0.61Short Ratio9.36Inst. Own83.10%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning04-3050-d Avg10.48200-d Avg12.521yr Est23.70

PHAT News

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
globenewswire.com
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phatho

Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in bel

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
businesswire.com
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceutica

NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses aft

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
prnewswire.com
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involvin

/PRNewswire/ -- Investors in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) were told the Company's fu

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
prnewswire.com
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investi

Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales fo

Phathom Pharmaceuticals Q2 Earnings Call Highlights
marketbeat.com
Phathom Pharmaceuticals Q2 Earnings Call Highlights

Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over ye

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
zacks.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals, Inc. (PHAT) reported break-even quarterly earnings per share versus the Zac

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
globenewswire.com
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host con

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
globenewswire.com
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 St

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
globenewswire.com
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease W

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
globenewswire.com
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Za

Earnings Scheduled For April 30, 2026
benzinga.com
Earnings Scheduled For April 30, 2026

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
globenewswire.com
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update o

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., A

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analyst

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has received a consensus recommendati

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Earnings Scheduled For October 30, 2025
benzinga.com
Earnings Scheduled For October 30, 2025

benzinga.com
Earnings Scheduled For August 7, 2025

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
benzinga.com
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday

benzinga.com
Earnings Scheduled For May 1, 2025

benzinga.com
Earnings Scheduled For March 6, 2025

benzinga.com
Earnings Scheduled For March 7, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earning

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023

benzinga.com
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mi

Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced a

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 469 companies hit new 52-week lows.

benzinga.com
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursda

benzinga.com
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday

Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatili

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's trading, 1214 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  During Tuesday's session, 454 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

    On Monday, 671 companies achieved new lows for the year.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  Tuesday morning saw 454 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  During Friday's session, 445 companies made new 52-week lows.